Related Experiment Videos
Advances in human immunodeficiency virus therapeutics
Patrick G Clay1, Betty J Dong, Suellyn J Sorensen
1Kansas City University of Medicine and Biosciences, Kansas City, MO 64106, USA. pclay@kcumb.edu
The Annals of Pharmacotherapy
|March 23, 2006
Summary
Recent advances in HIV management show promise with new therapies like receptor inhibitors and improved drug regimens. However, tolerability and adherence remain key challenges for long-term treatment success.
Area of Science:
- Infectious Diseases
- Virology
- Pharmacology
Background:
- Human Immunodeficiency Virus (HIV) infection remains a significant global health challenge.
- Effective management strategies are crucial for improving patient outcomes and quality of life.
Purpose of the Study:
- To review recent advancements in the therapeutic management of individuals with HIV infection.
- To highlight emerging antiretroviral therapies and their clinical implications.
Main Methods:
- Comprehensive literature search of MEDLINE (March 2003-February 2006) for antiretroviral therapy research.
- Review of abstracts and programs from major HIV conferences (January 2003-June 2005).
- Inclusion of studies on recently approved or investigational products, excluding topics previously covered in The Annals.
Main Results:
- Investigational CXCR4 and CCR5 receptor inhibitors show therapeutic promise.
- Tipranavir, a new protease inhibitor, is effective in highly resistant HIV cases but has combination limitations.
- Once-daily emtricitabine/tenofovir demonstrate superiority over lamivudine/zidovudine as backbone nucleoside analogs.
- Emerging pharmacokinetic considerations include age, gender, race, and drug discontinuation patterns.
Conclusions:
- Significant progress has been achieved in the treatment of HIV infection.
- Optimizing long-term regimen effectiveness is hindered by challenges in tolerability and patient adherence.